CRISPR-Cas9 guided RNA-based model for the silencing of spinal bulbar muscular atrophy: A functional genetic disorder
Authors:
- Muhammad NaveedMNMuhammad Naveed
- Tariq AzizTariq Aziz
- Muhammad Aqib ShabbirMSMuhammad Aqib Shabbir
- Mariam Abdulaziz AlkhateebMAMariam Abdulaziz Alkhateeb
- Saad AlghamdiSaad Alghamdi
- Ahmad O. BabalghithABAhmad O. Babalghith
- Ahad Amer AlsaiariAAAhad Amer Alsaiari
- Sahar A. AlshareefSASahar A. Alshareef
- Aminah A. BarqawiABAminah A. Barqawi
Open Access
- 8 October 2024
- journal article
- Published by CMB Association in Cellular and Molecular Biology
- Vol. 70 (9) , 74-80
Abstract
This study explores a novel therapeutic approach for spinal bulbar muscular atrophy (SBMA), a neurodegenerative disorder caused by a mutation in the Androgen Receptor (AR) gene. The aim is to investigate the potential of CRISPR-Cas9 technology in targeting the mutant AR gene to inhibit its production. The objectives include assessing the accuracy and efficacy of CRISPR-Cas9 guided RNAs in silencing the mutant gene and evaluating the feasibility of this approach as a treatment for SBMA. Computational and in-silico approaches are used to evaluate the feasibility of using CRISPR-Cas9 technology for treating SBMA. Computational analysis is used to design CRISPR-Cas9 guided RNAs targeting the mutant AR gene, assessing their on-target and off-target scores, GC content, and structural accuracy. In-silico simulations predict the potential therapeutic outcomes of the CRISPR-Cas9 approach in an artificial environment. Three guided RNA (gRNA) sequences were designed using the CHOPCHOP tool, targeting specific regions of the AR gene with high efficiency and 100% match. These gRNAs demonstrated effective targeting with minimal off-target scores and optimal GC content. Additionally, lentiCRISPR v2 plasmids were designed for the delivery of CRISPR materials, enabling high-efficiency multiplex genome editing of the AR gene. Thermodynamic ensemble predictions indicated favorable secondary structure stability of the designed gRNAs, further supporting their suitability for gene editing. The evaluation of designed gRNAs confirmed their strong binding ability to the target sequences, validating their potential as effective tools for genome editing. The study highlights the potential of CRISPR-Cas9 technology for targeting the Androgen Receptor gene associated with spinal bulbar muscular atrophy (SBMA). The findings support the feasibility of this approach for gene editing and suggest further exploration in preclinical and clinical settings. Recommendations include continued research to optimize CRISPR-Cas9 delivery methods and enhance specificity for therapeutic applications in SBMA.Keywords
All Related Versions
This publication has 20 references indexed in Scilit:
- CRISPR and iPSCs: Recent Developments and Future Perspectives in Neurodegenerative Disease Modelling, Research, and TherapeuticsNeurotoxicity Research, 2022
- NO-dependent vasodilation and deep tumor penetration for cascade-amplified antitumor performanceJournal of Controlled Release, 2022
- Human stem cell models of polyglutamine diseases: Sources for disease models and cell therapyExperimental Neurology, 2021
- Kennedy's disease: an under-recognized motor neuron disorderActa Neurologica Belgica, 2020
- Should spinal cord MRI be systematically performed for diagnosis and follow-up of multiple sclerosis? NoRevue Neurologique, 2020
- Molecular Mechanisms and Therapeutics for SBMA/Kennedy's DiseaseNeurotherapeutics, 2019
- Central nervous system abnormalities in spinal and bulbar muscular atrophy (Kennedy’s disease)Clinical Neurology and Neurosurgery, 2019
- Kennedy’s disease (spinal and bulbar muscular atrophy): a clinically oriented review of a rare diseaseJournal of Neurology, 2018
- Identification of the porcine homologous of human disease causing trinucleotide repeat sequencesneurogenetics, 2007
- No genetic association between the LRP receptor and sporadic or late-onset familial Alzheimer diseaseneurogenetics, 1998